Letícia Lemos Jardim1, Danyelle Romana Alves Rios2, Luíza Oliveira Perucci3, Lirlândia Pires de Sousa3, Karina Braga Gomes3, Luci Maria S Dusse4. 1. Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Brazil. 2. Campus Centro Oeste Dona Lindu, Universidade Federal de São João Del-Rei, Brazil. 3. Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Brazil. 4. Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Brazil. Electronic address: lucidusse@gmail.com.
Abstract
BACKGROUND: Preeclampsia (PE) is a multisystem disease characterized by the development of hypertension and proteinuria. Although PE etiology is not fully known, the placenta seems to play a central role in the development of disease. The inadequate placentation process results in a change in angiogenic factors levels, such as vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble form of endoglin (s-Eng) and soluble form of vascular endothelial growth factor receptor type 1 (sFlt-1). OBJECTIVE: The aim of this review was to clarify if the imbalance between pro-angiogenic and anti-angiogenic factors is associated with PE. CONCLUSION: It is known that inadequate placentation process is the primary mechanism suggested for PE occurrence and angiogenic factors are involved in this process. The state-of-the-art suggests that progress in grasp the imbalance of pro-angiogenic and anti-angiogenic factors is essential for the improvement of knowledge about PE. The development of prospective, longitudinal studies with serial determinations of these factors throughout pregnancy is needed to better assess the relevance of these markers for understanding the etiology, prevention, diagnosis, prognosis and treatment of this challenging disease.
BACKGROUND: Preeclampsia (PE) is a multisystem disease characterized by the development of hypertension and proteinuria. Although PE etiology is not fully known, the placenta seems to play a central role in the development of disease. The inadequate placentation process results in a change in angiogenic factors levels, such as vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble form of endoglin (s-Eng) and soluble form of vascular endothelial growth factor receptor type 1 (sFlt-1). OBJECTIVE: The aim of this review was to clarify if the imbalance between pro-angiogenic and anti-angiogenic factors is associated with PE. CONCLUSION: It is known that inadequate placentation process is the primary mechanism suggested for PE occurrence and angiogenic factors are involved in this process. The state-of-the-art suggests that progress in grasp the imbalance of pro-angiogenic and anti-angiogenic factors is essential for the improvement of knowledge about PE. The development of prospective, longitudinal studies with serial determinations of these factors throughout pregnancy is needed to better assess the relevance of these markers for understanding the etiology, prevention, diagnosis, prognosis and treatment of this challenging disease.
Authors: Carlos A Dias-Junior; Juanjuan Chen; Ning Cui; Charles L Chiang; Minglin Zhu; Zongli Ren; Jose S Possomato-Vieira; Raouf A Khalil Journal: Biochem Pharmacol Date: 2017-09-11 Impact factor: 5.858
Authors: Katherine Bianco; Matthew Gormley; Jason Farrell; Yan Zhou; Oliver Oliverio; Hannah Tilden; Michael McMaster; Susan J Fisher Journal: Prenat Diagn Date: 2016-07-25 Impact factor: 3.050